FDA Initiates Class II Recall of Advanced Pharmaceutical Technology's Unapproved Testosterone Cypionate Injection
Advanced Pharmaceutical Technology, Inc. faces an FDA Class II recall for its TESTO-200 Testosterone Cypionate Injection, marketed without an approved NDA/ANDA. This event underscores critical regulatory compliance failures, demanding immediate attention from procurement, regulatory affairs, and supply chain leaders to mitigate risks associated with unapproved pharmaceutical products and ensure robust supplier qualification.
FDA Mandates Class II Recall for Unapproved Testosterone Cypionate Injection
The U.S. Food and Drug Administration (FDA) has initiated a Class II recall (D-0531-2025) for TESTO-200, Testosterone Cypionate Injection USP, 2000mg/10ml (200mg/ml), manufactured by Advanced Pharmaceutical Technology, Inc. This voluntary, firm-initiated recall, announced on May 30, 2025, stems from a critical regulatory violation: the product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). The recall specifically targets Lot P-24-1, with an expiration date of February 28, 2027, encompassing 26 vials distributed across New York and New Jersey. For procurement directors and regulatory affairs heads, this event signals a fundamental breakdown in pre-market approval compliance. Marketing a drug without an FDA-approved NDA or ANDA means the product has not undergone the rigorous evaluation processes for safety, efficacy, and quality assurance. This exposes any entity in the supply chain – from distributors to healthcare providers – to significant regulatory, legal, and reputational risks. Companies must immediately verify the regulatory status of all sourced pharmaceutical products, particularly injectables, to prevent inadvertently distributing unapproved medications and ensure patient safety.
Advanced Pharmaceutical Technology's Operational Footprint and Product Scope
Advanced Pharmaceutical Technology, Inc. operates from its facility at 132 S Central Ave, Elmsford, NY 10523-3509, United States. The recalled product, TESTO-200, is a Testosterone Cypionate Injection, an androgen used in hormone replacement therapy. While the quantity involved in this specific recall is limited to 26 vials, the underlying issue of marketing an unapproved drug is severe and indicative of potential systemic regulatory compliance gaps at the facility. For supply chain VPs and business development executives, the localized nature of this recall (Elmsford, NY facility and NY, NJ distribution) does not diminish the gravity of the regulatory breach. Smaller manufacturers, while potentially offering competitive pricing or niche products, often present higher regulatory risks if their quality management systems and pre-market approval processes are not robust. This incident underscores the imperative for comprehensive supplier qualification audits that extend beyond financial viability to encompass thorough regulatory compliance checks, especially for controlled substances like Testosterone Cypionate. Relying on suppliers without verified FDA approvals can lead to costly recalls, market withdrawals, and significant legal liabilities.
Supply Chain Exposure and Immediate Market Impact in NY and NJ
The distribution pattern for the recalled TESTO-200 Testosterone Cypionate Injection was confined to New York and New Jersey. This localized distribution means that distributors, pharmacies, and healthcare providers operating within these two states are directly impacted by the Class II recall. The relatively small quantity of 26 vials of Lot P-24-1, while not indicative of widespread market saturation, still necessitates immediate action from all downstream entities to quarantine and return the affected product. For procurement directors and supply chain VPs, this situation highlights the critical importance of traceability within the supply chain. Companies must have robust systems in place to quickly identify and isolate affected lots, even for limited distributions, to comply with FDA directives and protect patient safety. Furthermore, this event serves as a stark reminder that even seemingly minor suppliers or niche products can pose significant regulatory exposure if fundamental compliance, such as NDA/ANDA approval, is overlooked. Business development teams should assess the potential for similar unapproved products to enter their supply chains, particularly when engaging with new or less established partners.
Mitigating Risk: Sourcing Alternatives for Testosterone Cypionate
The ChemLifeIntel Knowledge Graph does not currently identify specific alternative suppliers for Testosterone Cypionate Injection directly linked to Advanced Pharmaceutical Technology, Inc. This absence of pre-vetted alternatives means that any procurement teams or formulators who might have been sourcing this specific product, or similar compounds, from Advanced Pharmaceutical Technology, Inc. must immediately initiate a comprehensive search for new, FDA-approved sources. For procurement directors, the immediate priority is to identify manufacturers holding active Abbreviated New Drug Applications (ANDAs) for Testosterone Cypionate Injection. This process involves rigorous due diligence, including reviewing FDA Orange Book listings, conducting supplier audits, and verifying manufacturing capabilities and quality systems. Qualification timelines for new pharmaceutical suppliers, especially for injectables, can be extensive, typically ranging from 6 to 18 months depending on the complexity of the product and the supplier's existing certifications. Companies should prioritize suppliers with a strong history of FDA compliance and a diverse geographic manufacturing footprint to enhance supply chain resilience and mitigate future regulatory risks.
Regulatory Landscape: Broader Scrutiny on Injectable Products
While specific prior regulatory actions against Advanced Pharmaceutical Technology, Inc. are not detailed in the ChemLifeIntel Knowledge Graph, this recall occurs within a broader context of heightened FDA scrutiny on pharmaceutical manufacturing and product approvals. Recent parallel events, such as Essential Wellness Pharma's Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, and an FDA hearing impacting Amgen's Tavneos market future, underscore the agency's active enforcement posture across the life sciences industry. For regulatory affairs heads and business development executives, these events collectively signal that the FDA is rigorously monitoring compliance, particularly for injectable products where sterility and pre-market authorization are paramount. The marketing of an unapproved drug, as seen with Advanced Pharmaceutical Technology, Inc.'s Testosterone Cypionate, represents a severe violation that can trigger substantial enforcement. Companies must ensure their internal regulatory intelligence functions are robust, continuously tracking FDA actions and evolving compliance expectations to proactively identify and mitigate risks across their product portfolios and supplier networks.
Remediation Pathways and Future Regulatory Implications
The Class II recall of TESTO-200 Testosterone Cypionate Injection by Advanced Pharmaceutical Technology, Inc. is currently 'Ongoing,' indicating that the firm is in the process of executing the recall and addressing the underlying regulatory deficiencies. The FDA will expect a comprehensive and timely response from Advanced Pharmaceutical Technology, Inc., detailing the root cause analysis for marketing an unapproved drug and outlining robust corrective and preventive actions (CAPA) to ensure future compliance. For regulatory affairs and business development executives, the implications of such a fundamental breach are significant. Failure to adequately remediate the issue could lead to further escalated enforcement actions, including FDA Warning Letters, import alerts (if applicable to future products), injunctions, product seizures, or even civil and criminal penalties. This incident serves as a critical reminder that pre-market approval is non-negotiable for pharmaceutical products in the U.S. market. Companies engaging in M&A or partnership discussions must conduct exhaustive regulatory due diligence to identify and quantify such liabilities, as they can severely impact valuation, market access, and long-term business viability.